Floatz logo

L19IL2/L19TNF

Cutaneous Neuroendocrine Carcinoma

Philogen S.p.A.UNKNOWNPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

44 Active assets in the Cutaneous Neuroendocrine Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 2/3BB
Ifx-Hu2.0
TuHURA Biosciences, Inc.
Phase 2/3B
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
Durvalumab
Ariceum Therapeutics GmbH
Phase 2B

View all 50 →

Same molecule, other indications

L19IL2/L19TNF is also rated in:

squamous cell carcinomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
skin basal cell carcinomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
Kaposi's sarcomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →